Showing 331-340 of 353 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Modulation of beta cell mRNA Translation in Type 1 Diabetes | Beckman Research Institute of the City of Hope | Farooq Syed | Cures | 01-September-2024 to 31-March-2027 | $444.138,25 |
| Non-invasive immunoimaging of islet transplant rejection | Beckman Research Institute of the City of Hope | Fouad Kandeel | Cures | 01-June-2023 to 31-May-2027 | $750.000,00 |
| Novel Cell-free DNA and RNA Dynamics in Islet Transplant | Beckman Research Institute of the City of Hope | Fouad Kandeel | Cures | 01-August-2026 to 31-July-2028 | $600.000,00 |
| Pilot Clinical Trial of Allogenic Islet Transplantation under the Abdominal Anterior Rectus Sheath for Advancing Treatment of Type 1 Diabetes | Beckman Research Institute of the City of Hope | Fouad Kandeel | Cures | 01-October-2026 to 30-September-2028 | $800.000,00 |
| Do Islet Somatic Mutations Contribute to T1D Age at Onset? | Beckman Research Institute of the City of Hope | Melanie Shapiro | Cures | 01-March-2026 to 28-February-2027 | $100.000,00 |
| Clinical Trial of Denosumab for Type 1 Diabetes | Beckman Research Institute of the City of Hope | Rupangi Vasavada | Cures | 01-October-2023 to 30-November-2027 | $2.232.400,00 |
| A novel approach to overcome innate immunity in beta-cell replacement therapy for type 1 diabetes | Baylor Research Institute | Bashoo Naziruddin | Cures | 01-January-2025 to 31-December-2027 | $749.769,68 |
| Understanding Disease Mechanisms Underlying Type 1 Diabetes | Baylor College of Medicine | Ashok Balasubramanyam | Cures | 01-November-2024 to 31-October-2027 | $967.091,04 |
| Unraveling the Influence of Obesity on Progression Along Preclinical Stages of Type 1 Diabetes | Baylor College of Medicine | Maria Redondo | Cures | 01-June-2025 to 31-May-2028 | $1.124.188,00 |
| Phase II Study of Oral HLA DQ8 Inhibitor in Adults with Type-I Diabetes | Aurimi Therapeutics | Nandan Padukone | Cures | 01-September-2026 to 31-August-2030 | $1.900.000,00 |